Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Barriers to blood pressure control initiatives: Regional diversity, inadequate measurement techniques, guideline inconsistencies, and health disparities.

Izzo JL Jr.

J Clin Hypertens (Greenwich). 2019 Feb;21(2):204-207. doi: 10.1111/jch.13466. Epub 2019 Jan 4. No abstract available.

2.

Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.

Izzo JL Jr, Zappe DH, Jia Y, Hafeez K, Zhang J.

J Cardiovasc Pharmacol. 2017 Jun;69(6):374-381. doi: 10.1097/FJC.0000000000000485.

PMID:
28338503
3.

Response to "A Short Insight on Two Different Aspects of Arterial Stiffness"; Moving Forward or Backward?

Izzo JL Jr, Gavish B.

Am J Hypertens. 2017 Apr 1;30(4):e3-e4. doi: 10.1093/ajh/hpw203. No abstract available.

PMID:
28158321
4.

Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice.

Izzo JL Jr, Jia Y, Zappe DH.

J Clin Hypertens (Greenwich). 2017 Feb;19(2):143-150. doi: 10.1111/jch.12891. Epub 2016 Sep 1.

5.

Hypertension and aging in rural Haiti: results from a preliminary survey.

Polsinelli VB, Satchidanand N, Singh R, Holmes D, Izzo JL Jr.

J Hum Hypertens. 2017 Feb;31(2):138-144. doi: 10.1038/jhh.2016.52. Epub 2016 Jul 28.

PMID:
27465982
6.

Controversies in hypertension: is lower blood pressure always better?

Tobe SW, Izzo JL Jr.

J Am Soc Hypertens. 2016 Aug;10(8):618-20. doi: 10.1016/j.jash.2016.06.027. Epub 2016 Jun 29. No abstract available.

PMID:
27436129
7.

Arterial Stiffness: Going a Step Beyond.

Gavish B, Izzo JL Jr.

Am J Hypertens. 2016 Nov 1;29(11):1223-1233. doi: 10.1093/ajh/hpw061.

PMID:
27405964
8.

Renal denervation for human hypertension: is there a future?

Izzo JL Jr, Tobe SW.

J Am Soc Hypertens. 2016 May;10(5):390-2. doi: 10.1016/j.jash.2016.02.016. Epub 2016 Mar 8.

PMID:
27049792
9.

Is there a preferred diuretic class for patients with renal impairment and hypertension?

Izzo JL Jr, Tobe SW.

J Am Soc Hypertens. 2016 Apr;10(4):282-4. doi: 10.1016/j.jash.2016.02.008. Epub 2016 Feb 23.

PMID:
26979914
10.

Age should not be a primary consideration in the management of hypertension.

Izzo JL Jr.

J Am Soc Hypertens. 2016 Jan;10(1):12-5. doi: 10.1016/j.jash.2015.11.003. Epub 2015 Dec 1. No abstract available.

PMID:
26850523
11.

How should BP be measured in the office?

Tobe SW, Izzo JL Jr.

J Am Soc Hypertens. 2016 Mar;10(3):189-90. doi: 10.1016/j.jash.2016.01.005. Epub 2016 Jan 11. No abstract available.

PMID:
26839184
12.

Should age determine hypertension management? Recommendations from current guidelines.

Izzo JL Jr, Tobe SW.

J Am Soc Hypertens. 2016 Jan;10(1):7-9. doi: 10.1016/j.jash.2016.01.002. Epub 2016 Jan 6.

PMID:
26794655
13.

Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination.

Izzo JL Jr, Khan SU, Saleem O, Osmond PJ.

J Am Soc Hypertens. 2015 Jul;9(7):526-35. doi: 10.1016/j.jash.2015.03.009. Epub 2015 Mar 28.

PMID:
26116459
14.

Response to "Central blood pressure physiology" a (more) critical review (Schultz et al.).

Izzo JL Jr.

Am J Hypertens. 2015 May;28(5):692. doi: 10.1093/ajh/hpv030. Epub 2015 Mar 25. No abstract available.

PMID:
25810008
15.

Brachial vs. central systolic pressure and pulse wave transmission indicators: a critical analysis.

Izzo JL Jr.

Am J Hypertens. 2014 Dec;27(12):1433-42. doi: 10.1093/ajh/hpu135. Epub 2014 Sep 18. Review.

PMID:
25233859
16.

Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.

Lewin AJ, Kereiakes DJ, Chrysant SG, Izzo JL Jr, Oparil S, Lee J, Fernandez V, Melino M.

Ethn Dis. 2014 Winter;24(1):41-7.

PMID:
24620447
17.

Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.

Lewin AJ, Izzo JL Jr, Melino M, Lee J, Fernandez V, Heyrman R.

Drugs Aging. 2013 Jul;30(7):549-60. doi: 10.1007/s40266-013-0072-1.

18.

Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.

Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Melino M, Lee J, Fernandez V, Heyrman R.

Cardiovasc Diabetol. 2012 Oct 30;11:134. doi: 10.1186/1475-2840-11-134.

19.

Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril.

Izzo JL Jr, Yedlapati SH, Faheem SM, Younus U, Osmond PJ.

J Am Soc Hypertens. 2012 Nov-Dec;6(6):399-404. doi: 10.1016/j.jash.2012.08.007. Epub 2012 Oct 26.

PMID:
23107894
20.

Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.

Chrysant SG, Littlejohn T 3rd, Izzo JL Jr, Kereiakes DJ, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.

Am J Cardiovasc Drugs. 2012 Aug 1;12(4):233-43. doi: 10.2165/11634160-000000000-00000.

PMID:
22799613
21.

Value of combined thiazide-loop diuretic therapy in chronic kidney disease: heart failure and renin-angiotensin-aldosterone blockade.

Izzo JL Jr.

J Clin Hypertens (Greenwich). 2012 May;14(5):344. doi: 10.1111/j.1751-7176.2012.00614.x. Epub 2012 Apr 11. No abstract available.

22.

Home and clinic blood pressure responses in elderly individuals with systolic hypertension.

Cushman WC, Duprez DA, Weintraub HS, Purkayastha D, Zappe D, Samuel R, Izzo JL Jr.

J Am Soc Hypertens. 2012 May-Jun;6(3):210-8. doi: 10.1016/j.jash.2012.03.001.

PMID:
22520932
23.

Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.

Menne J, Izzo JL Jr, Ito S, Januszewicz A, Katayama S, Chatzykirkou C, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, Haller H; ROADMAP investigators.

J Hypertens. 2012 Apr;30(4):811-8; discussion 818. doi: 10.1097/HJH.0b013e328351856d. Erratum in: J Hypertens. 2012 Aug;30(8):1679.

PMID:
22418908
24.

Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.

Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.

J Clin Hypertens (Greenwich). 2012 Mar;14(3):149-57. doi: 10.1111/j.1751-7176.2011.00588.x. Epub 2012 Jan 24.

25.

Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity.

Weintraub HS, Duprez DA, Cushman WC, Zappe DH, Purkayastha D, Samuel R, Izzo JL Jr.

Cardiovasc Drugs Ther. 2012 Apr;26(2):145-55. doi: 10.1007/s10557-011-6365-x.

PMID:
22311004
26.

Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress.

Izzo JL Jr, Rajpal M, Karan S, Srikakarlapudi S, Osmond PJ.

J Am Soc Hypertens. 2012 Mar-Apr;6(2):117-23. doi: 10.1016/j.jash.2011.12.001. Epub 2012 Jan 20.

PMID:
22264722
27.

24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.

Izzo JL Jr, Chrysant SG, Kereiakes DJ, Littlejohn Iii T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.

J Clin Hypertens (Greenwich). 2011 Dec;13(12):873-80. doi: 10.1111/j.1751-7176.2011.00544.x. Epub 2011 Oct 28.

28.

Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study.

Chrysant SG, Izzo JL Jr, Kereiakes DJ, Littlejohn T 3rd, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.

J Am Soc Hypertens. 2012 Mar-Apr;6(2):132-41. doi: 10.1016/j.jash.2011.09.003. Epub 2011 Oct 26. Erratum in: J Am Soc Hypertens. 2013 Jul-Aug;7(4):325.

PMID:
22030597
29.

Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results.

Izzo JL Jr, Weintraub HS, Duprez DA, Purkayastha D, Zappe D, Samuel R, Cushman WC.

J Clin Hypertens (Greenwich). 2011 Oct;13(10):722-30. doi: 10.1111/j.1751-7176.2011.00498.x. Epub 2011 Jul 14.

30.

Benefits of antihypertensive drugs when blood pressure is below 140/90 mmHg.

Izzo JL Jr.

Pol Arch Med Wewn. 2011 Sep;121(9):303-9. Review.

31.

Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome.

Weinberger MH, Izzo JL Jr, Purkayastha D, Weitzman R, Black HR.

J Am Soc Hypertens. 2011 Nov-Dec;5(6):489-97. doi: 10.1016/j.jash.2011.08.005. Epub 2011 Sep 17.

PMID:
21925996
32.

Angiotensin-converting enzyme inhibitors.

Izzo JL Jr, Weir MR.

J Clin Hypertens (Greenwich). 2011 Sep;13(9):667-75. doi: 10.1111/j.1751-7176.2011.00508.x. Epub 2011 Jul 18. Review.

33.

Hypertension in diverse populations: a New York State Medicaid clinical guidance document.

Wrobel MJ, Figge JJ, Izzo JL Jr.

J Am Soc Hypertens. 2011 Jul-Aug;5(4):208-29. doi: 10.1016/j.jash.2011.05.003. Review.

PMID:
21771564
34.

Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy.

Duprez DA, Weintraub HS, Cushman WC, Purkayastha D, Zappe D, Samuel R, Izzo JL Jr.

Blood Press Monit. 2011 Aug;16(4):186-96. doi: 10.1097/MBP.0b013e32834944e9.

PMID:
21747241
35.

Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues.

Izzo JL, Zion AS.

Ther Adv Cardiovasc Dis. 2011 Jun;5(3):169-78. doi: 10.1177/1753944711409615. Epub 2011 May 23. Review.

PMID:
21606125
36.

Value of Angiotensin receptor blocker therapy in diabetes.

Izzo JL Jr, Zion AS.

J Clin Hypertens (Greenwich). 2011 Apr;13(4):290-5. doi: 10.1111/j.1751-7176.2011.00447.x. Review.

37.

Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results.

Zion AS, Izzo JL Jr.

Expert Rev Cardiovasc Ther. 2011 Apr;9(4):421-7. doi: 10.1586/erc.11.23. Epub 2011 Mar 18. Review.

PMID:
21417713
38.

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators.

N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.

39.

Adherence and persistence with taking medication to control high blood pressure.

Hill MN, Miller NH, Degeest S; American Society of Hypertension Writing Group, Materson BJ, Black HR, Izzo JL Jr, Oparil S, Weber MA.

J Am Soc Hypertens. 2011 Jan-Feb;5(1):56-63. doi: 10.1016/j.jash.2011.01.001. Review.

PMID:
21320699
40.

Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).

Januszewicz A, Ritz E, Viberti G, Mimran A, Rabelink AJ, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Haller H.

J Hum Hypertens. 2011 Nov;25(11):679-85. doi: 10.1038/jhh.2010.111. Epub 2010 Dec 9.

PMID:
21150933
41.

Are there benefits of antihypertensive therapy beyond blood pressure lowering?

Izzo JL Jr.

Curr Hypertens Rep. 2010 Dec;12(6):440-7. doi: 10.1007/s11906-010-0160-0. Review.

PMID:
20978874
42.

Combination therapy in hypertension.

Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, Izzo JL Jr, Oparil S, Weber MA.

J Am Soc Hypertens. 2010 Mar-Apr;4(2):90-8. doi: 10.1016/j.jash.2010.03.001.

PMID:
20400053
43.

ASH position paper: dietary approaches to lower blood pressure.

Appel LJ, Giles TD, Black HR, Izzo JL Jr, Materson BJ, Oparil S, Weber MA.

J Am Soc Hypertens. 2010 Mar-Apr;4(2):79-89. doi: 10.1016/j.jash.2010.03.004.

PMID:
20400052
44.

Treatment of hypertension in patients with diabetes--an update.

Bakris GL, Sowers JR, Glies TD, Black HR, Izzo JL Jr, Materson BJ, Oparil S, Weber MA.

J Am Soc Hypertens. 2010 Mar-Apr;4(2):62-7. doi: 10.1016/j.jash.2010.03.005. No abstract available.

PMID:
20400050
45.

When and how to use self (home) and ambulatory blood pressure monitoring.

Pickering TG, White WB, Giles TD, Black HR, Izzo JL, Materson BJ, Oparil S, Weber MA.

J Am Soc Hypertens. 2010 Mar-Apr;4(2):56-61. doi: 10.1016/j.jash.2010.03.003.

PMID:
20400049
46.

Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension.

Izzo JL Jr, Purkayastha D, Hall D, Hilkert RJ.

J Hum Hypertens. 2010 Jun;24(6):403-9. doi: 10.1038/jhh.2009.80. Epub 2009 Nov 5.

PMID:
19890370
47.

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H.

Diabetologia. 2010 Jan;53(1):49-57. doi: 10.1007/s00125-009-1577-3. Epub 2009 Oct 30.

48.

Seasonal variation in haemodynamics and blood pressure-regulating hormones.

Radke KJ, Izzo JL Jr.

J Hum Hypertens. 2010 Jun;24(6):410-6. doi: 10.1038/jhh.2009.75. Epub 2009 Sep 24.

PMID:
19776756
49.

Lessons from the ACCOMPLISH trial.

Izzo JL.

Pol Arch Med Wewn. 2009 Jun;119(6):344-6. No abstract available.

50.

ASH Position Paper: Dietary approaches to lower blood pressure.

Appel LJ; American Society of Hypertension Writing Group, Giles TD, Black HR, Izzo JL Jr, Materson BJ, Oparil S, Weber MA.

J Clin Hypertens (Greenwich). 2009 Jul;11(7):358-68. doi: 10.1111/j.1751-7176.2009.00136.x.

Supplemental Content

Support Center